Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2001-02-13
2009-08-11
Yaen, Christopher H (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
Reexamination Certificate
active
07572891
ABSTRACT:
This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
REFERENCES:
patent: 5972353 (1999-10-01), Zavada et al.
patent: WO 95/34650 (1995-12-01), None
patent: WO 95/34650 (1995-12-01), None
patent: WO 2005/037083 (2005-04-01), None
patent: WO 2005/037083 (2005-04-01), None
Steger et al (Br. J. Cancer 1995; 72:101-107).
Uemura et al (Br J Cancer Oct. 1999;81(4):741-6).
Grabmaier et al (Int. J. Cancer 2000; 85:865-870).
Bhattacharya-Chatterjee M et al Curr Opin Mol Ther. Feb. 2001;3(1):63-9).
Tao et al (Nature Apr. 1993, 362:755-758).
Batova et al. (1999) “The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro”Clin. Cancer Res. 5: 4259-4263.
Battaglia et al. (2000) “The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer of erythropoiesis”Exp. Hematol., 28: 490-498.
Brändle et al. (1996) “A Mutated HLA-A2 Molecule Recognized by Autologous Cytotoxic T Lymphocytes on a Human Renal Cell Carcinoma”J. Exp. Med., 183:2501-2508.
Brossart et al. (1998) “Her-2
eu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes”Cancer Res., 58: 732-736.
Cao et al. (1999) “Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells”Immunol., 97: 616-625.
Condon et al. (1996) “DNA-based immunization by in vivo transfection of dendritic cells”Nature Med., 2(10):1122-1128.
Fisher et al. (1997) “High-Dose Aldesleukin in Renal Cell Carcinoma: Long-Term Survival Update”Cancer J. Sci. Amer., 3: S70.
Gaugler et al. (1996) “A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma”Immunogenetics, 44:323-330.
Grabmaier et al. (2000) “Molecular Cloning and Immunogenicity of Renal Cell Carcinoma-Associated Antigen G250”Intl. J. Cancer, 85: 865-870.
Hall et al. (1999) “DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival ina SCID mouse model of acute myeloid leukemia.”Leukemia, 13: 629-633.
Hill et al. (1995) “The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications.”J. Leukocyte Biol. 58: 634-642.
Hinkel et al. (2000) “Immunomodulatory Dendritic Cells Generated From Nonfractionated Bulk Peripheral Blood Mononuclear Cell Cultures Induce Growth of Cytotoxic T Cells Against Renal Cell Carcinoma.”J. Immunother., 23(1): 83-93.
Huang et al. (1994) “Role of Bone Marrow Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens.”Science, 264: 961-965.
Jonuleit et al.(1996) “Cytokines and thier effects on maturation, differentiation and migration of dendritic cells.”Archives of Dermatological Res. 289: 1-8.
Lee et al. (1999) “Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression.”J Immunol., 163: 6292-6300.
Liu (1998) “Vaccine developments”Nature Med., 4(5): 515-519.
Mach et al. (2000) “Differences in Dendritic Cells Stimulated in Vivo by Tumors Engineered to Secrete Granulocyte-Macrophage Colony-stimulating Factor or Flt3-Ligand”Cancer Res., 60: 3239-3246.
Mulders et al. (1999)“Presentation of Renal Tumor Antigens by Human Dendritic Cells Activates Tumor-infiltrating Lymphocytes against Autologous Tumor: Implications for Live Kidney Cancer Vaccines”Clin. Cancer Res., 5:445-454.
Nestle et al. (1998) “Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.”Nature Med., 4(3): 328-332.
Opavský et al. (1996) “HumanMN/CA9Gene, a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships.”Genomics, 33: 480-487.
Parhar et al. (1992) “Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines”Europ. Cytokine Network, 3(3): 299-306.
Parkhurst et al. (1996) “Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues.”J. Immunol., 157: 2539-2548.
Pulendran et al. (1999) “Distinct dendritic cell subsets differentially regulate the class of immune response in vivo”Proc. Natl. Acad. Sci, USA, 96:1036-1041.
Rammensee et al. (1993) “Peptides Naturally Presented by MHC Class I Molecules.”Annual Rev. Immunol., 11: 213-244.
Rescigno et al. (1998) “Dendritic Cell Survival and Maturation Are Regulated by Different Signaling Pathways.”J. Exp. Med., 188(11): 2175-2180.
Rosenberg et al. (1999) “Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine.”J. Immunol., 163:1690-1695.
Roth et al. (2000) “Granulocyte Macrophage Colony-stimulating Factor and Interleukin 4 Enhance the Number and Antigen-presenting Activity of Circulating CD14+ and CD83+ Cells in Cancer Patients”Cancer Res., 60:1934-1941.
Roussel et al. (1990) “Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16− CD56− large granular lymphocyte LAK cells”Clin. Exp. Immunol., 82: 416-421.
Simons et al. (1997) “Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer”Cancer Res. 57: 1537-1546.
Soiffer et al. (1998) “Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma”Proc. Natl. Acad. Sci., USA, 95: 13141-13146.
Tripathi et al. (1999) “Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF”Hybridoma18(2): 193-202.
Ulmer et al. (1998) “Protective CD4+ and CD8+ T Cells against Influenza Virus Induced by Vaccination with Nucleoprotein DNA”J Virol., 72(7): 5648-5653.
Vissers et al. (1999) “The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocytes”Cancer Res., 59:5554-5559.
Wang et al. (1999) “Human tumor antigens: implications for cancer vaccine development”J. Mol. Med., 77:640-655.
Wong et al. (1985) “Human GM-CSF: Molecular Cloning of the Complementary DNA and Purification of the Natural and Recombinant Proteins”Science228: 810-815.
Xu et al. (2000) “Genetic modulation of tumor antigen presentation”Trends in Biotech. 18: 167-172.
Yang et al. (1999) “Murine dendritic cells transfected wtih human GP100 elicit both antigen-specific CB8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.”Intl. J
Belldegrun Arie
Tso Cho-Lea
The Regents of the University of California
Townsend and Townsend / and Crew LLP
Yaen Christopher H
LandOfFree
Kidney-specific tumor vaccine directed against kidney tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kidney-specific tumor vaccine directed against kidney tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kidney-specific tumor vaccine directed against kidney tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4106721